Characteristics of interventional hemophilia trials reporting race and ethnicity data
| . | Total . | Race or ethnicity Not reported . | Race or ethnicity Reported . | P value∗ . |
|---|---|---|---|---|
| N (%) . | N (%) . | N (%) . | ||
| Total | 129 (100.0) | 62 (48.0) | 67 (52.0) | |
| Phase | .31 | |||
| 1 | 13 (10.1) | 6 (46.2) | 7 (53.8) | |
| 2 | 23 (17.8) | 13 (56.5) | 10 (43.5) | |
| 3 | 68 (52.7) | 29 (42.6) | 39 (57.4) | |
| 4 | 22 (17.1) | 11 (50) | 11 (50) | |
| Missing | 3 (2.3) | 3 (100) | 0 (0) | |
| Trial length (y) | .07 | |||
| <2 | 48 (37.2) | 24 (50) | 24 (50) | |
| 2-5 | 56 (43.4) | 31 (55.4) | 25 (44.6) | |
| ≥5 | 25 (19.4) | 7 (28) | 18 (72) | |
| Study completion date | .001 | |||
| 2007-2012 | 36 (27.9) | 31 (86.1) | 5 (13.9) | |
| 2013-2016 | 40 (31) | 31 (77.5) | 9 (22.5) | |
| 2017-2022 | 53 (41.1) | 0 (0) | 53 (100) | |
| Sponsor type | .20 | |||
| Industry | 122 (94.6) | 57 (46.7) | 65 (53.3) | |
| Academic | 7 (5.4) | 5 (71.4) | 2 (28.6) | |
| Hemophilia type | ||||
| Hem A | 76 (58.9) | 35 (46.1) | 41 (53.9) | .36 |
| Hem B | 29 (22.5) | 17 (58.6) | 12 (41.4) | |
| Hem A and B | 23 (17.8) | 9 (39.1) | 14 (60.9) | |
| Missing | 1 | |||
| Severity† | .87 | |||
| All severities | 10 (7.8) | 4 (40) | 6 (60) | |
| Moderate and severe | 18 (14) | 9 (50) | 9 (50) | |
| Severe | 79 (61.2) | 37 (46.8) | 42 (53.2) | |
| Missing | 22 (17.1) | 12 (54.5) | 10 (45.5) | |
| Included inhibitor patients | 36 (22.9) | 12 (33.3) | 24 (66.7) | .07 |
| Number of participants | .65 | |||
| <30 | 48 (37.2) | 25 (52.1) | 23 (47.9) | |
| 30-59 | 30 (23.3) | 15 (50) | 15 (50) | |
| 60+ | 51 (39.5) | 22 (43.1) | 29 (56.9) | |
| Number of countries | .48 | |||
| 1-3 | 21 (37.5) | 11 (52.4) | 10 (47.6) | |
| 4-10 | 13 (23.2) | 8 (61.5) | 5 (38.5) | |
| >10 | 22 (39.3) | 9 (40.9) | 13 (59.1) | |
| Site location(s)‡ | ||||
| United States | 84 (65.1) | 41 (48.8) | 43 (51.2) | .82 |
| North America | 89 (69) | 44 (49.4) | 45 (50.6) | .64 |
| South America | 27 (20.9) | 11 (40.7) | 16 (59.3) | .39 |
| Europe | 95 (73.6) | 45 (47.4) | 50 (52.6) | .79 |
| Africa | 27 (20.9) | 12 (44.4) | 15 (55.6) | .67 |
| Asia | 92 (71.3) | 43 (46.7) | 49 (53.3) | .64 |
| World Bank income classification§ | ||||
| Low-middle income | 42 (32.6) | 18 (42.9) | 24 (57.1) | .41 |
| Upper-middle income | 90 (70.0) | 44 (49.0) | 46 (51.1) | .78 |
| High income | 111 (86.1) | 55 (49.6) | 56 (50.5) | .40 |
| Mean (standard deviation) | ||||
| Number of participants analyzed | 62.3 (58.25) | 51.9 (43.42) | 71.9 (68.14) | .005 |
| Mean age | 26.8 (13.18) | 27.5 (13.51) | 26.1 (12.97) | .777 |
| Number of countries | 7.4 (6.58) | 7.3 (6.63) | 7.5 (6.58) | .844 |
| . | Total . | Race or ethnicity Not reported . | Race or ethnicity Reported . | P value∗ . |
|---|---|---|---|---|
| N (%) . | N (%) . | N (%) . | ||
| Total | 129 (100.0) | 62 (48.0) | 67 (52.0) | |
| Phase | .31 | |||
| 1 | 13 (10.1) | 6 (46.2) | 7 (53.8) | |
| 2 | 23 (17.8) | 13 (56.5) | 10 (43.5) | |
| 3 | 68 (52.7) | 29 (42.6) | 39 (57.4) | |
| 4 | 22 (17.1) | 11 (50) | 11 (50) | |
| Missing | 3 (2.3) | 3 (100) | 0 (0) | |
| Trial length (y) | .07 | |||
| <2 | 48 (37.2) | 24 (50) | 24 (50) | |
| 2-5 | 56 (43.4) | 31 (55.4) | 25 (44.6) | |
| ≥5 | 25 (19.4) | 7 (28) | 18 (72) | |
| Study completion date | .001 | |||
| 2007-2012 | 36 (27.9) | 31 (86.1) | 5 (13.9) | |
| 2013-2016 | 40 (31) | 31 (77.5) | 9 (22.5) | |
| 2017-2022 | 53 (41.1) | 0 (0) | 53 (100) | |
| Sponsor type | .20 | |||
| Industry | 122 (94.6) | 57 (46.7) | 65 (53.3) | |
| Academic | 7 (5.4) | 5 (71.4) | 2 (28.6) | |
| Hemophilia type | ||||
| Hem A | 76 (58.9) | 35 (46.1) | 41 (53.9) | .36 |
| Hem B | 29 (22.5) | 17 (58.6) | 12 (41.4) | |
| Hem A and B | 23 (17.8) | 9 (39.1) | 14 (60.9) | |
| Missing | 1 | |||
| Severity† | .87 | |||
| All severities | 10 (7.8) | 4 (40) | 6 (60) | |
| Moderate and severe | 18 (14) | 9 (50) | 9 (50) | |
| Severe | 79 (61.2) | 37 (46.8) | 42 (53.2) | |
| Missing | 22 (17.1) | 12 (54.5) | 10 (45.5) | |
| Included inhibitor patients | 36 (22.9) | 12 (33.3) | 24 (66.7) | .07 |
| Number of participants | .65 | |||
| <30 | 48 (37.2) | 25 (52.1) | 23 (47.9) | |
| 30-59 | 30 (23.3) | 15 (50) | 15 (50) | |
| 60+ | 51 (39.5) | 22 (43.1) | 29 (56.9) | |
| Number of countries | .48 | |||
| 1-3 | 21 (37.5) | 11 (52.4) | 10 (47.6) | |
| 4-10 | 13 (23.2) | 8 (61.5) | 5 (38.5) | |
| >10 | 22 (39.3) | 9 (40.9) | 13 (59.1) | |
| Site location(s)‡ | ||||
| United States | 84 (65.1) | 41 (48.8) | 43 (51.2) | .82 |
| North America | 89 (69) | 44 (49.4) | 45 (50.6) | .64 |
| South America | 27 (20.9) | 11 (40.7) | 16 (59.3) | .39 |
| Europe | 95 (73.6) | 45 (47.4) | 50 (52.6) | .79 |
| Africa | 27 (20.9) | 12 (44.4) | 15 (55.6) | .67 |
| Asia | 92 (71.3) | 43 (46.7) | 49 (53.3) | .64 |
| World Bank income classification§ | ||||
| Low-middle income | 42 (32.6) | 18 (42.9) | 24 (57.1) | .41 |
| Upper-middle income | 90 (70.0) | 44 (49.0) | 46 (51.1) | .78 |
| High income | 111 (86.1) | 55 (49.6) | 56 (50.5) | .40 |
| Mean (standard deviation) | ||||
| Number of participants analyzed | 62.3 (58.25) | 51.9 (43.42) | 71.9 (68.14) | .005 |
| Mean age | 26.8 (13.18) | 27.5 (13.51) | 26.1 (12.97) | .777 |
| Number of countries | 7.4 (6.58) | 7.3 (6.63) | 7.5 (6.58) | .844 |
Hem, hemophilia.
χ2 tests were used to measure differences across categorical variables and t tests were used to measure differences across continuous variables (age, number of participants).
There were no trials recorded as having only mild or mild and moderate participants.
Includes at least 1 site in the region listed.
Trials were counted if they had at least 1 site income category listed. Incomes are based on World Bank income classification, there were no sites in low-income countries.